HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Data Supplement Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via ISI Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Danilov, S. M. Articles by Albrecht, R. F. Search for Related Content PubMed PubMed Citation Articles by Danilov, S. M. Articles by Albrecht, R. F. Related Collections Molecular Diagnostics and Genetics Other Areas of Clinical Chemistry

Detection of Mutated Angiotensin I-Converting Enzyme by Serum/Plasma Analysis Using a Pair of Monoclonal Antibodies

¹ Department of Anesthesiology, University of Illinois at Chicago, Chicago, IL; Departments of² Medicine, ³ Pharmacology/Toxicology, and⁴ Internal Medicine, University Medical Center, Nijmegen, The Netherlands;⁵ Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands;

^aaddress correspondence to this author at: Anesthesiology Research Center, University of Illinois at Chicago, 1819 W. Polk St. (M/C 519), Chicago, IL 60612; fax 312-996-9680, e-mail danilov@uic.edu

The first 300 words of the full text of this article appear below.

Angiotensin I-converting enzyme (ACE; CD143) is a Zn²⁺ carboxydipeptidase that plays a key role in the regulation of blood pressure and in the development of vascular pathology and remodeling (1)(2)(3). ACE is constitutively expressed on the surface of endothelial cells, macrophages, dendritic cells, and various other cell types (4)(5). Somatic ACE contains two homologous domains, N- and C-terminal, each with a catalytic center (2)(6). ACE has been accepted as a CD marker, CD143 (4)(6).

Soluble serum ACE originates from endothelial cells by proteolytic cleavage by an unidentified protease of the Arg¹²⁰³–Ser¹²⁰⁴ peptide bond in the stalk region near the C-terminal transmembrane sequence of the ACE molecule (7)(8)(9)(10)(11). At physiologic conditions, the concentration of ACE in blood is very stable (12), whereas the ACE concentration in serum is often significantly increased in granulomatous diseases (in particular, sarcoidosis) or Gaucher disease (13)(14)(15)(16)(17)(18).

We described a Pro1199Leu mutation, located in the juxtamembrane stalk region of ACE (19)(20), that explained a considerable familial increase in blood ACE activity in individuals from several Dutch families (19). The same phenotype and autosomal-dominant inheritance pattern have been described in Japan (21) and Italy(22). Despite the fact that patients with this mutation at first scrutiny do not have clinical abnormalities (19), the finding of increased ACE has led to confusion for treating physicians (23)(24).

We recently observed reduced binding of soluble ACE in Dutch patients with a Pro1199Leu substitution detected by a new monoclonal antibody (mAb), 1B3, which recognizes . . . [Full Text of this Article]